Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle

Whole transcriptome sequencing analysis revealed key RNA profiles and toxicity in mice after chronic exposure to microplastics

Investigating the long-term effects of microplastics (MPs) in vivo is necessary for evaluating its biological toxicity. Previously, we showed that MPs elicit vascular dysfunctions in atherosclerotic mice. However, the effects of long-term treatment with environmental levels of MPs on biological functions and RNA expression profiles in wild-type mice are unknown. Here, C57BL/6 mice were administered 1000 μg/L MPs through their drinking water for 180 days. Transcriptomic analyses, biochemical analysis, and histopathological examination were conducted to determine the key signals and molecular mechanisms triggered by MPs in vivo using whole transcriptome sequencing, enzyme-linked immunosorbent assay, and histopathological analysis. Notably, our data revealed that MPs aggravated vascular lesions and organ injuries, particularly liver, kidney, and heart injuries. Additionally, MPs exacerbated oxidative injuries by inhibiting the activities of antioxidant enzymes and increasing the levels of the serum biochemistry indicator of organ damage. RNA sequencing of vascular tissues showed that 674 mRNAs, 39 lncRNAs, 196 miRNAs, and 565 circRNAs were abnormally expressed in MPs-treated mice compared with the untreated group. Pathway enrichment analyses identified pathways linked to the toxicity of MPs, including lysosomal, NOD-like receptor, and peroxisome proliferator-activated receptor pathways. Additionally, competing endogenous RNA networks were constructed and hub RNAs were identified using bioinformatics analysis. Taken together, our data suggested that toxicity induced by long-term exposure to MPs continually presents with extensive changes in biological features and global gene expression profiles. Our data provides new insights into the biological toxicity of MPs.

Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma

Glioblastoma multiforme (GBM) is the most common form of primary brain cancer and has the highest morbidity rate and current treatments result in a bleak 5-year survival rate of 5.6%. Interstitial therapy is one option to increase survival. Drug delivery by interstitial therapy most commonly makes use of a polymer implant encapsulating a drug which releases as the polymer degrades. Interstitial therapy has been extensively studied as a treatment option for GBM as it provides several advantages over systemic administration of chemotherapeutics. Primarily, it can be applied behind the blood–brain barrier, increasing the number of possible chemotherapeutic candidates that can be used and reducing systemic levels of the therapy while concentrating it near the cancer source. With interstitial therapy, multiple drugs can be released locally into the brain at the site of resection as the polymer of the implant degrades, and the release profile of these drugs can be tailored to optimize combination therapy or maintain synergistic ratios. This can bypass the blood–brain barrier, alleviate systemic toxicity, and resolve drug resistance in the tumor. However, tailoring drug release requires appropriate consideration of the complex relationship between the drug, polymer, and formulation method. Drug physicochemical properties can result in intermolecular bonding with the polymeric matrix and affect drug distribution in the implant depending on the formulation method used. This review is focused on current works that have applied interstitial therapy towards GBM, discusses polymer and formulation methods, and provides design considerations for future implantable biodegradable materials.